Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Of the enrolled participants, 41% had type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
The cited source says what the claim attributes to it.
In the citing paper
“The selective nonsteroidal MRA finerenone was examined in the Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF) trial of people with symptomatic HFpEF (ejection fraction ≥40%) and was found to reduce the risk of”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [303]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationPitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSpironolactone for heart failure with preserved ejection fraction
Pitt, B., Pfeffer, M. A., Assmann, S. F., Boineau, R., Anand, I. S., Claggett, B., Clausell, N., Desai, A. S., Diaz, R., Fleg, J. L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1313731 · Cited by 2,809
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationCardiovascular events with finerenone in kidney disease and type 2 diabetes
Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110956 · Cited by 1,814
Self-citation
Cited by
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf284 · Cited by 355
Palaniappan, L. P., Allen, N. B., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Bansal, N., Currie, M. E., Earlie, R. S., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001412 · Cited by 242
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 225
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E., Sato, K., Teramoto, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0002 · Cited by 191
The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction
Packer, M. (2025) · JACC · doi:10.1016/j.jacc.2025.06.055 · Cited by 173
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
Jhund, P. S., Talebi, A., Henderson, A. D., Claggett, B. L., Vaduganathan, M., Desai, A. S., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01733-1 · Cited by 190
“In a subgroup analysis, the benefit of finerenone was consistent regardless of background SGLT2 inhibitor use 8 and this is consistent with similar findings in trials of finerenone in patients with diabetes and chronic kidney disease.”
ResultSelf-citationVaduganathan, M., Filippatos, G., Claggett, B. L., Desai, A. S., Jhund, P. S., Henderson, A., Brinker, M., Kolkhof, P., Schloemer, P., Lay-Flurrie, J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03264-4 · Cited by 158
“Finer-enone has been shown to reduce the risk of cardiovascular events and kidney failure in patients with CKD with type 2 diabetes (T2D) 15,16 and has recently been shown to reduce worsening HF events in patients with HF with mildly reduced or preserved ejection fraction 17 .”
Self-citationCardiovascular disease in chronic kidney disease
Marx-Schütt, K., Cherney, D. Z. I., Jankowski, J., Matsushita, K., Nardone, M., & Marx, N. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf167 · Cited by 185
Theodorakis, N., & Nikolaou, M. (2025) · Biomolecules · doi:10.3390/biom15020213 · Cited by 175
Peikert, A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Litwin, S. E., Zile, M. R., Desai, A. S., Jhund, P. S., Butt, J. H., Lam, C. S. P., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf057 · Cited by 132
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Heart Failure with Preserved Ejection Fraction
Cannata, A. N., & McDonagh, T. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmcp2305181 · Cited by 109
Finerenone and Kidney Outcomes in Patients With Heart Failure
Mc Causland, F. R., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Brinker, M., Perkins, R., Scheerer, M. F., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.091 · Cited by 86
Self-citation2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
Kittleson, M. M., Benjamin, E. J., Blumer, V., Harrington, J., Januzzi, J. L., McMurray, J. J. V., & Vest, A. R. (2025) · JACC · doi:10.1016/j.jacc.2025.05.008 · Cited by 79
Self-citationJudge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R. J., Cronin, L., Green, J. B., Agrawal, N., Arimoto, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae263 · Cited by 91
Self-citationZile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072679 · Cited by 74
Docherty, K. F., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Mueller, K., Viswanathan, P., Scalise, A. V., Lam, C. S. P., Senni, M., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.072011 · Cited by 84
“15 Another potential contributing factor to the relatively higher NT-proBNP concentrations in patients with LVEF ≥ 60% may have been the high proportion of patients (42”
Self-citationVaduganathan, M., Claggett, B. L., Kulac, I. J., Miao, Z. M., Desai, A. S., Jhund, P. S., Henderson, A. D., BRINKER, M. D., Lay‐Flurrie, J., Viswanathan, P., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.072055 · Cited by 87
Self-citationMutruc, V., Bologa, C., Șorodoc, V., Ceasovschih, A., Morărașu, B. C., Șorodoc, L., Catar, O., & Lionte, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082833 · Cited by 89
“…the EF spectrum [113–116 , Moreover, finerenone demonstrated significant efficacy in reducing cardiovascular events and the worsening of HF in patients with HFpEF or HPmrEF [121], increasing its potential as one of the main pillars of therapy in patients with HFmrEF or HFpEF, along with SGLT2is.”
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 160
Edelmann, F., Wachter, R., Duvinage, A., Mueller, S., Fegers‐Wustrow, I., Schwarz, S., Christle, J. W., Pieske‐Kraigher, E., Seyfarth, M., Knapp, M., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03342-7 · Cited by 77
“3).”
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 159
Self-citationRosano, G. M. C., Teerlink, J. R., Kinugawa, K., Bayés‐Genís, A., Chioncel, O. D., Fang, J. C.-T., Greenberg, B., Ibrahim, N. E., Imamura, T., Inomata, T., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3646 · Cited by 72
Self-citationVascular (dys)function in the failing heart
Liberale, L., Duncker, D. J., Hausenloy, D. J., Kraler, S. C., Bøtker, H. E., Podesser, B. K., Heusch, G., & Kleinbongard, P. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01163-w · Cited by 62
Vardeny, O., Vaduganathan, M., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F. M., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.4539 · Cited by 54
Self-citationFinerenone, Obesity, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction
Butt, J. H., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Lay‐Flurrie, J., Viswanathan, P., Lage, A. Z., Scheerer, M. F., Lam, C. S. P., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.111 · Cited by 56
Self-citationRoutine Spironolactone in Acute Myocardial Infarction
Jolly, S. S., d’Entremont, M.-A., Pitt, B., Lee, S. F., Mian, R. I., Tyrwhitt, J., Kedev, S., Montalescot, G., Cornel, J. H., Stankovic, G. R., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2405923 · Cited by 54
Self-citationPeikert, A., Fontana, M., Solomon, S. D., & Thum, T. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf524 · Cited by 74
“112,113 114–116 Moreover, angiotensin receptor neprilysin inhibitor (ARNI) treatment favourably altered makers of ECM homoeostasis in the PARAGON-HF (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction) trial of patients with symptomatic HF and LVEF ≥ 45%.”
Self-citationFinerenone in Patients With a Recent Worsening Heart Failure Event
Desai, A. S., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Jhund, P. S., Cunningham, J. W., Borentain, M., Lay‐Flurrie, J., Viswanathan, P., Rohwedder, K., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.004 · Cited by 64
Self-citationJCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 67
Aldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
Fioretti, F., Testani, J. M., Tio, M. C., Pitt, B., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.012 · Cited by 56
Self-citationSawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 44
“The cardiovascular benefit of finerenone in CKD patients with diabetes was primarily attributable to the reduction in the risk of HHF and was similar in FINEARTS-HF for patients with HFpEF [54].”
Savarese, G., Schiattarella, G. G., Lindberg, F., Anker, M. S., Bayés‐Genís, A., Bäck, M., Braunschweig, F., Bucciarelli‐Ducci, C., Butler, J., Cannata, A. N., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3676 · Cited by 58
Self-citationTrends in Heart Failure Mortality in Sweden Between 1997 and 2022
Lindberg, F., Benson, L., Dahlström, U., Lund, L. H., & Savarese, G. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3506 · Cited by 53
Kobayashi, M., Pitt, B., Ferreira, J. P., Rossignol, P., Girerd, N., & Zannad, F. M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf225 · Cited by 53
“60 In contrast, primary aldosterone is defined as autonomous or non-suppressible renin-independent aldosterone production and affects around 20% of patients with TRH. 61 Guideline-recommended screening for primary aldosteronism remains underutilized ( 2”
Self-citationGorica, E., Geiger, M. A., Venanzio, L. D., Atzemian, N., Kleeberger, J., Grigorian, D., Mongelli, A., Veseli, B. E., Mohammed, S. A., Ruschitzka, F. T., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02774-w · Cited by 55
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF
Yang, M., Henderson, A. D., Talebi, A., Atherton, J. J., Chiang, C.-E., Chopra, V., Comin-Colet, J., Kosiborod, M. N., Kerr Saraiva, J. F., Claggett, B. L., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.023 · Cited by 41
Self-citationMineralocorticoid Receptor Antagonists in Heart Failure: An Update
Ferreira, J. P., Pitt, B., & Zannad, F. M. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011629 · Cited by 47
“32 Finerenone was the first MRA to convincingly improve HF outcomes in HFpEF in an adequately powered and monitored trial.”
Self-citationAldosterone Synthase Inhibitors: A Revival for Treatment of Renal and Cardiovascular Diseases
Azizi, M., Mallart-Riancho, J., & Amar, L. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae823 · Cited by 47
Witteles, R., García-Pavía, P., Damy, T., Grogan, M., Sheikh, F., Morbach, C., Bender, S., Exter, J., Eraly, S., & Fontana, M. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.008 · Cited by 39
Pabón, M. A., Filippatos, G. S., Claggett, B. L., Miao, M. Z., Desai, A. S., Jhund, P. S., Henderson, A. D., BRINKER, M. D., Schloemer, P., Hofmeister, L. H., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.03.429 · Cited by 43
Self-citationHulot, J., ter Maaten, J. M., Bayés‐Genís, A., Halliday, B. P., Metra, M., Moura, B., Petrie, M. C., Savarese, G., Senni, M., Linhout, S. V., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3732 · Cited by 47
Self-citationHeart failure with reduced ejection fraction
Cannata, A. N., Crespo-Leiro, M. G., Bromage, D. I., Ruschitzka, F., & McDonagh, T. A. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01851-3 · Cited by 44
Mineralocorticoid Antagonism in Heart Failure
Chang, J., Ambrosy, A. P., Vardeny, O., Spall, H. G. C. V., Mentz, R. J., & Sauer, A. J. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.08.007 · Cited by 46
Self-citationTheodorakis, N., Kreouzi, M., Hitas, C., Anagnostou, D., & Nikolaou, M. (2024) · Diagnostics · doi:10.3390/diagnostics14232677 · Cited by 46
“The above mechanisms can potentially explain why finerenone, a non-steroidal mineralocorticoid receptor antagonist, has been proven to be effective in improving hard endpoints in patients with HFpEF, according to the FINE-ARTS trial [22].”
Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos
Lee, C. J. M., Kosyakovsky, L. B., Khan, M. S., Wu, F., Chen, G., Hill, J. A., Ho, J. E., Foo, R., & Zannad, F. M. (2025) · Circulation Research · doi:10.1161/circresaha.125.325602 · Cited by 39
Self-citationInitial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF
Matsumoto, S., Jhund, P. S., Henderson, A. D., Bauersachs, J. K., Claggett, B. L., Desai, A. S., BRINKER, M. D., Schloemer, P., Viswanathan, P., Mares, J. W., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.020 · Cited by 36
Self-citationChimura, M., Wang, X., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Fonseca, C., Gonçalvesová, E., Katova, T., Mueller, K., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.4613 · Cited by 32
Self-citationFrom cardiorenal to cardiovascular–kidney–metabolic syndromes
Braunwald, E. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae775 · Cited by 32
Central Adiposity or Hypertension
Packer, M., Butler, J., Lam, C. S. P., Zannad, F. M., Vaduganathan, M., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.036 · Cited by 32
Self-citationAldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
Mazzieri, A., Timio, F., Patera, F., Trepiccione, F., Bonomini, M., & Reboldi, G. (2024) · Kidney & Blood Pressure Research · doi:10.1159/000542621 · Cited by 29
“…FINE-HEART pre-planned individual-level pooled analysis [62] of 18,991 participants enrolled in the above-mentioned ef fi cacy trials [57, 58, 61], con fi rmed fi nerenone ef fi cacy on all-cause mortality, cardiovascular events, and kidney outcomes in patients with overlapping…”
Pyne, L., Rossignol, P., Giles, C., Junek, M., Mark, P. B., Gallagher, M., de Zoysa, J., Devereaux, P. J., & Walsh, M. W. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01153-5 · Cited by 27
Shokravi, A., Seth, J., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02900-8 · Cited by 41
“Additionally, finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), has shown benefit in patients with diabetic kidney disease (DKD) and heart failure with preserved ejection fraction (HFpEF) [3–5].”
HFpEF and MASLD: converging mechanisms and clinical implications
Capone, F., Häseli, S. P., Liu, L., Strocchi, S., Langenberg, C., Lusis, A. J., Pietzner, M., Muoio, D. M., Rider, O. J., Raman, B., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01257-z · Cited by 37
“In HFpEF, the FINEARTS-HF trial 403 demonstrated the efficacy of finerenone, a non-steroidal mineralocorticoid receptor antagonist, in reducing worsening HF events or cardiovascular mortality in patients with LVEF >40% compared with placebo, leading to FDA approval for its use in adults with HF…”
Self-citationChimura, M., Petrie, M. C., Schou, M., Martínez, F. A., Henderson, A. D., Claggett, B. L., Desai, A. S., Kolkhof, P., Viswanathan, P., Lage, A. Z., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012437 · Cited by 27
Self-citationTailoring Medical Therapy for Heart Failure with Preserved Ejection Fraction
Inciardi, R. M., Riccardi, M., Savarese, G., Metra, M., Vaduganathan, M., & Solomon, S. D. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3558 · Cited by 26
Self-citationFinerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Viswanathan, P., Kolkhof, P., Schloemer, P., Amarante, F., Lam, C. S. P., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00309-7 · Cited by 39
“15,16,19 The trial protocol (appendix 1 pp 1–284) was approved by the ethics committees at all participating institutions, and all participants provided written informed consent.”
Self-citationClinical implications of mineralocorticoid receptor overactivation
Mouhayyar, C. E., Chhikara, M., Tang, M., & Nigwekar, S. U. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae346 · Cited by 26
“…FINEARTS-HF79, a recently published clinical trial evaluating finerenone’s efficacy and safety in patients with HF and preserved or mildly reduced ejection fraction, showed that finerenone resulted in a significant decrease in composite of HF events and CV related deaths compared to placebo [79 ].”
Fernando, K., Connolly, D. L., Darcy, E., Evans, M., Hinchliffe, W., Holmes, P., & Strain, W. D. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01738-3 · Cited by 31
“The FINEARTS-HF (NCT04435626) trial further established finerenone’s cardiovascular benefits, showing a significant reduction in the risk of cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction [42].”
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Ferreira, J. P., Vasques‐Nóvoa, F., Saraiva, F. A., Oliveira, A., Almeida, J., Batista, A. B., Barbosa, A., Ferreira, A. F., Costa, C., Diaz, S. O., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.05.033 · Cited by 30
Self-citationRasalam, R. R., Sindone, A. P., Deed, G., Audehm, R. G., & Atherton, J. J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15205 · Cited by 28
Self-citationMatsumoto, S., Henderson, A. D., Jhund, P. S., Bauersachs, J. K., Chioncel, O. D., Claggett, B. L., Colet, J. C., Desai, A. S., Filippatos, G., Lam, C. S. P., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0848 · Cited by 29
Self-citationRashid, A. M., Khan, M. S., Cherney, D. Z. I., Mehta, A. N., Rangaswami, J., Shafi, T., & Butler, J. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000752 · Cited by 25
Finerenone in Heart Failure With Improved Ejection Fraction
Pabón, M. A., Vardeny, O., Vaduganathan, M., Desai, A. S., Claggett, B. L., Kulac, I. J., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.1101 · Cited by 28
Self-citationVaduganathan, M., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F. M., Pitt, B., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2024.3782 · Cited by 30
Self-citationButt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Chiang, C., Linssen, G. C. M., Saldarriaga, C., Saraiva, J. F. K., Sato, N., Schou, M., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.1775 · Cited by 28
Self-citationKaneko, T., Kagiyama, N., Okazaki, S., Amano, M., Satô, Y., Ohno, Y., Obokata, M., Sato, K., Morita, K., Kubo, S., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf511 · Cited by 21
“28 Although surgical treatment yielded an even lower HR of 0.39 in our previous study, 7 this may reflect the additive benefit of concomitant interventions such as tricuspid valve surgery.”
InfluentialSuspected de novo heart failure in outpatient care: the REVOLUTION HF study
Anderson, L., Bayés‐Genís, A., Bodegård, J., Mullin, K., Gustafsson, S., Rosano, G. M. C., & Sundström, J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf034 · Cited by 21
“Recent clinical trial data also demonstrate the efficacy of novel MRAs in patients with HF and a left ventricular ejection fraction ≥ 40%, 16 regardless of baseline SGLT2 inhibitor use, 17 thus suggesting that non-steroidal MRAs could also be considered for early initiation, prior to ejection…”
Maintaining kidney health in aging societies: a JSN and ERA call to action
Ortíz, A., Kramer, A., Rychlík, I., Nangaku, M., Yanagita, M., Jager, K. J., Caskey, F. J., Stel, V. S., Kashihara, N., Kuragano, T., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf068 · Cited by 25
“…antagonists (MRAs), sodium–glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have multiple beneficial effects on diverse age-associated NCDs, including CKD, CVD and the overweight/obesity/type 2 diabetes mellitus spectrum [25 , 27 – 31 ] (Fig.”
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 36
Self-citationTime to Significant Benefit of Finerenone in Patients With Heart Failure
Vaduganathan, M., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F. M., Pitt, B., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.09.018 · Cited by 21
Self-citationGawryś, O., Kala, P., Sadowski, J., Melenovský, V., Sandner, P., & Červenka, L. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177175 · Cited by 23
Self-citationHeart Failure in Older Patients: An Update
Montalto, M., D'Ignazio, F., Camilli, S., Francesco, S. D., Fedele, M., Landi, F., & Gallo, A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061982 · Cited by 26
“…(mean age 72 years) and the meta-analysis by Jhund et al., there is comprehensive evidence that non-steroidal MRAs (finerenone) in HFmrEF or HFpEF patients resulted in a significant lower rate of a composite of total worsening HF events and death from cardiovascular causes than placebo [93,96].”
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 24
“[63].”
InfluentialSelf-citationKeramida, K., López‐Fernández, T., Anker, M. S., Petrie, M. C., Ameri, P., Anderson, L. J., Bergler-Klein, J. K., Deswal, A. M., Farmakis, D. T., Ibáñez, B., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70005 · Cited by 24
Self-citationWhy Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF?
Kondo, T., Henderson, A. D., Docherty, K. F., Jhund, P. S., Vaduganathan, M., Solomon, S. D., & McMurray, J. J. V. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.033 · Cited by 20
Self-citationWorsening heart failure: progress, pitfalls, and perspectives
Fonseca, C., Rui, B., Franco, F., Brenda, M., Pimenta, J., Sarmento, P., Silva‐Cardoso, J., & Brito, D. A. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10497-z · Cited by 26
Self-citationCunningham, J. W., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P. S., Lam, C. S. P., Senni, M., Shah, S. J., Voors, A. A., Zannad, F. M., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3694 · Cited by 18
Self-citationThe Role of Coronary Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
Tzoumas, A., Tapp, D. N., Crousillat, D. R., Honigberg, M. C., Lozano, P. F. R., Aggarwal, N. R., Ebong, I., Briller, J. E., de Oliveira, G. M., Harrington, C. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.102345 · Cited by 23
Neuen, B. L., Heerspink, H. J. L., Perkovic, V., Cherney, D. Z. I., Lam, C. S. P., Tuttle, K. R., Wanner, C., Sarafidis, P. A., Anker, S. D., Filippatos, G. S., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01009-3 · Cited by 24
Self-citationNationwide, Pragmatic, Direct-to-Patient Primary Aldosteronism Testing Program
Brown, J. M., Tsai, L. C., Abel, E. E., Ferrebus, A., Moore, A. E., Niebuhr, Y., Bacare, B., Honzel, B., Milks, J., Foote, K., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.24648 · Cited by 20
Rodrigues, M. M., & Falcão, L. M. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133182 · Cited by 20
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101069 · Cited by 27
“…demonstrated a 16% reduction in the primary outcome of total worsening HF events and CV death over 32 months (rate ratio, 0.84; 95% CI: 0.74 to 0.95; P = 0.007) [95], despite a mean UACR of 18mg/g (suggesting normal or mildly reduced kidney function) finerenone still led to a 30% reduction in UACR.”
InfluentialSelf-citationOstrominski, J. W., Harrington, J., Claggett, B. L., Filippatos, G. S., Desai, A. S., Jhund, P. S., Henderson, A. D., Lam, C. S. P., Senni, M., Shah, S. J., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.039 · Cited by 17
Self-citationShokravi, A., Seth, J., Lu, N., & Mancini, G. B. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00248-2 · Cited by 17
“Baseline information on the 11 newly included trials [7, 8, 41–49] can be found in Supplementary Table S2.”
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Koirala, S., Sunnaa, M., Bernier, T. D., & Oktay, A. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02129-z · Cited by 17
Guidelines for treating heart failure
Kittleson, M. M. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.10.002 · Cited by 19
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 24
The interplay between heart failure and chronic kidney disease
Lala, A., Levin, A., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16371 · Cited by 22
Finerenone effects on biomarkers: an analysis from the FIGARO-DKD trial
Berger, M., MacNamara, A., Ferreira, J. P., Kolkhof, P., Voss, S., Skubala, A., Scalise, A. V., Goea, L., Nkulikiyinka, R., Pitt, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf316 · Cited by 18
Self-citationiCARDIO Alliance Global Implementation Guidelines on Heart Failure 2025
Chopra, V., Khan, M. S., Abdelhamid, M., Abraham, W. T., Amir, O., Anker, S. D., Atherton, J. J., Bacal, F., von Bardeleben, R. S., Brito, D. A., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.05.094 · Cited by 34
Self-citationKaul, S. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.036 · Cited by 19
Vaduganathan, M., Claggett, B. L., Chatur, S., Desai, A. S., Jhund, P. S., Vardeny, O., Merkely, B. P., Martínez, F. A., Colet, J. C., Saraiva, J. F. K., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04037-3 · Cited by 20
“In this cross-trial analysis, we identified pivotal trials that supported the regulatory evaluation of therapies approved by the US Food and Drug Administration (as of August 2025) for the management of HFmrEF/ HFpEF.”
InfluentialSelf-citationNew drug therapies for hypertension
Azizi, M., Tuttle, K. R., Brown, J. M., Piskorz, D. L., Kario, K., & Williams, B. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02064-1 · Cited by 20
New strategies for the treatment of hyperkalemia
Masi, S., Dalpiaz, H., Piludu, S., Piani, F., Fiorini, G., & Borghi, C. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.10.016 · Cited by 19
Cardiovascular Efficacy and Safety of Finerenone: A Meta‐Analysis of Randomized Controlled Trials
Ahmed, M., Ahsan, A., Shafiq, A., Maniya, M. T., Jain, H., Iqbal, J., Naveed, M. A., Ahmed, R., Rana, J. S., Fudim, M., et al. (2025) · Clinical Cardiology · doi:10.1002/clc.70065 · Cited by 20
Butt, J. H., Jhund, P. S., Henderson, A. D., Claggett, B. L., Desai, A. S., Lam, C. S. P., BRINKER, M. D., Schloemer, P., Viswanathan, P., Lage, A. Z., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3649 · Cited by 17
Self-citationAlfarano, M., Marchionni, G., Costantino, J., Ballatore, F., Verardo, R., Miraldi, F., Ciciarello, F., Petramala, L., Letizia, C., Frustaci, A., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101762 · Cited by 26
Okuno, T., Kagami, K., Harada, T., Hoshiga, M., Ishii, H., & Obokata, M. (2025) · Circulation Journal · doi:10.1253/circj.cj-25-0214 · Cited by 20
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Vaduganathan, M., Claggett, B., Jhund, P. S., Desai, A. S., Henderson, A. D., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., Voors, A. A., Zannad, F., Abidin, I. Z., Alcocer-Gamba, M. A., Atherton, J. J., Bauersachs, J., Chang-Sheng, M., Chiang, C.-E., Chioncel, O., Chopra, V., Comin-Colet, J., Filippatos, G., Fonseca, C., Gajos, G., Goland, S., Goncalvesova, E., Kang, S., Katova, T., Kosiborod, M. N., Latkovskis, G., Lee, A. P.-W., Linssen, G. C. M., Llamas-Esperón, G., Mareev, V., Martinez, F. A., Melenovský, V., Merkely, B., Nodari, S., Petrie, M. C., Saldarriaga, C. I., Saraiva, J. F. K., Sato, N., Schou, M., Sharma, K., Troughton, R., Udell, J. A., Ukkonen, H., Vardeny, O., Verma, S., von Lewinski, D., Voronkov, L., Yilmaz, M. B., Zieroth, S., Lay-Flurrie, J., van Gameren, I., Amarante, F., Kolkhof, P., & Viswanathan, P.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston (S.D.S., M.V., B.C., A.S.D.); British Heart Foundation Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (J.J.V.M., P.S.J., A.D.H., M.C.P.), and Bayer, Reading (J.L.-F.) — both in the United Kingdom; National Heart Centre Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); University of Michigan School of Medicine, Ann Arbor (B.P.); University of Milano-Bicocca and Papa Giovanni XXIII Hospital, Bergamo (M. Senni), and the Department of Cardiology, University of Brescia, and ASST “Spedali Civili” Hospital, Brescia (S.N.) — all in Italy; Northwestern University Feinberg School of Medicine, Chicago (S.J.S.); University Medical Center Groningen, Groningen (A.A.V.), the Department of Cardiology, Hospital Group Twente, Almelo (G.C.M.L.), and Bayer, Hoofddorp (I.G.) — all in the Netherlands; Université de Lorraine, INSERM Clinical Inv...
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Vaduganathan, Muthiah
- Claggett, Brian
- Jhund, Pardeep S.
- Desai, Akshay S.
- Henderson, Alasdair D.
- Lam, Carolyn S.P.
- Pitt, Bertram
- Senni, Michele
- Shah, Sanjiv J.
- Voors, Adriaan A.
- Zannad, Faiez
- Abidin, Imran Zainal
- Alcocer-Gamba, Marco Antonio
- Atherton, John J.
- Bauersachs, Johann
- Chiang, Chern-En
- Chioncel, Ovidiu
- Chopra, Vijay
- Filippatos, Gerasimos
- Fonseca, Cândida
- Gajos, Grzegorz
- Goland, Sorel
- Kosiborod, Mikhail N.
- Latkovskis, Gustavs
- Lee, Alex Pui-Wai
- Linssen, Gerard C.M.
- Melenovský, Vojtěch
- Merkely, Béla
- Nodari, Savina
- Petrie, Mark C.
- Saldarriaga, Clara Inés
- Saraiva, Jose Francisco Kerr
- Sato, Naoki
- Schou, Morten
- Troughton, Richard
- Udell, Jacob A.
- Ukkonen, Heikki
- Vardeny, Orly
- Verma, Subodh
- von Lewinski, Dirk
- Voronkov, Leonid
- Zieroth, Shelley
- Kolkhof, Peter
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-10-24
- Volume
- 391
- Issue
- 16
- Pages
- 1475-1485
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4402101139
- Cited by
- 893
- References
- 21
- Citations by year
- 2026: 414 · 2025: 398 · 2024: 81
- FWCI
- 268.66
- Type
- journal article
- Language
- en
- Open access
- green
- hal.univ-lorraine.fr
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Bayer
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- finerenone, heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, mineralocorticoid receptor antagonists, non-steroidal mineralocorticoid receptor antagonists, cardiovascular mortality, hyperkalemia, hypokalemia, FINEARTS-HF trial, left ventricular ejection fraction, heart failure hospitalization, drug safety
- MeSH terms
- Aged, Aged, 80 and over, Mineralocorticoid Receptor Antagonists, Double-Blind Method, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Stroke Volume, Treatment Outcome, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.